We scan new podcasts and send you the top 5 insights daily.
Warma says drugs can completely eliminate plaque while patients continue to decline, and plaque-binding drugs carry ARIA risk. He argues the industry now sees toxic oligomers as the subspecies driving cognitive decline, making plaque a less relevant or insufficient target. That shift explains why ProMIS is not chasing plaque clearance as its main endpoint.
The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.
Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.
The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.
After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.
Traditional Alzheimer's drug development has heavily targeted extracellular amyloid-beta plaques with limited success. Retro Biosciences focuses upstream on cellular autophagy failure—the breakdown of the cell's natural system for recycling broken, misfolded proteins. Enhancing intracellular autophagy clears internal protein gunk before it becomes extracellular pathology, offering a biologically grounded, disease-modifying approach rather than treating visible end-stage debris.
Current amyloid treatments like Kisunla face biological limits in early symptomatic Alzheimer's because tau pathology takes over later in disease progression. Eli Lilly's Trailblazer 3 trial investigates treating patients with amyloid biological hallmarks before symptoms appear. Ricks argues that amyloid intervention matters most upstream, which could redefine clinical efficacy and testing paradigms across neurology.
Voyager's CEO explains that amyloid and tau are not independent culprits in Alzheimer's. Tau clumps naturally with age in a small brain region. Amyloid accumulation then acts as a trigger, causing this "tau fire" to spread catastrophically, suggesting treatments may need to address both.
The speaker positions NKEVs not as a monotherapy but as a foundational treatment. A key hypothesis is that by clearing amyloid from the brain's vasculature, NKEVs could mitigate the brain bleeding (ARIA) side effects that have plagued anti-amyloid antibody therapies. This would make combination treatments both safer and more effective.
Neil Warma says ProMIS designed PMN310 to bind only toxic oligomer species of amyloid beta, avoiding plaque. He notes plaque-clearing drugs can cause ARIA swelling/bleeding, and plaque removal alone doesn't stop cognitive decline. He says the antibody must avoid plaque while hitting upstream oligomers. This selectivity is the core best-in-class bet.
Focusing on breaking up protein aggregates may be intervening too late in neurodegenerative diseases. A more effective strategy could be targeting neuroinflammation, an upstream mechanism that potentially drives damage before irreversible protein aggregation begins and becomes a self-feeding cycle.